Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes

Xenobiotica

Volumn 30, Issue 3, 2000, Pages 273-284

  Sahi, J ^a   Hamilton, G ^b   Sinz, M ^a   Barros, S ^b   Huang, S M ^c   Lesko, L J ^c   LeCluyse, E L ^b,d  

^a PFIZER INC   (United States)

^b and Assessment   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A4; DEXAMETHASONE; RIFAMPICIN; TERFENADINE; TROGLITAZONE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; MALE; MONKEY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

ANIMALIA;

EID: 0034028127     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982500237668     Document Type: Article

References (32)

1. Antonucci, T., McLain, R., Whitcomb, R. et al., 1997, Impaired glucose tolerance is normalized by treatment with the thiazoldinedione, troglitazone. Diabetes Care, 20, 188-193.
2. Burgess, S. J., Singer, G. G. and Brennan, D. C., 1998, Effect of troglitazone on cyclosporine whole blood levels. Transplantation, 66, 1399-1400.
3. Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M. et al., 1997, Treatment with oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. Journal of Clinical Investigation, 100, 530-537.
4. Cowie, C. C. and Eberhardt, M. S. (eds), 1996, Diabetes 1996 Vital Statistics (Alexandria: American Diabetes Association).
5. Dunnett, G. W., 1964, New tables for multiple comparisons with a control. Biometrics 20, 482-491.
6. Fujiwara, T., Yoshioka, U. et al., 1998, Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes, 37, 1549-1558.
7. Kaplan, B., Friedman, G., Jacobs, M. et al., 1998, Potential interaction of troglitazone and cyclosporine. Transplantation, 65, 1399-1400.
8. Kumar, S., Boulton, A. J. M., Beck-Nielsen H. et al., 1996, Troglitazone, an insulin action enhancer, improves metabolic control in type II diabetes patients. Diabetelogia, 39, 701-709.
9. LeCluyse, E. L., Bullock, P. and Parkinson, A., 1996b, Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes. Advanced Drug Delivery Reviews, 22, 133-186.
10. Lecluyse, E. L., Bullock, P., Parkinson, A. and Hochman, J. H., 1996a, Cultured rat hepatocytes. In R. T. Borchardt, G. Wilson and P. Smith (eds), Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism (New York: Plenum), pp. 121-159.
11. Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T. and Kliewer, S. A., 1998, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. Journal of Clinical Investigation, 102, 1016-1023.
12. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A. et al., 1995, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). Journal of Biological Chemistry, 270, 12953-12956.
13. Kocarek, T. A., Schuetz, E. G., Strom, S. C., Fisher, R. A. and Guzelian, P. S., 1995, Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metabolism and Disposition, 23, 415-421.
14. Koup, J. R., Anderson, G. and Loi, C. M., 1998, Effect of troglitazone on urinary excretion of cortisol and 6β-hydroxycortisol. Journal of Clinical Pharmacology, 38, 815-818.
15. Loi, C. M., Knowlton, P. W., Stern, R. et al., 1998a, Effect of troglitazone on steady-state pharmacokinetics of digoxin. Journal of Clinical Pharmacology, 38, 178-183.
16. Loi, C. M., Malcolm, Y. Randinitis, E. et al., 1999a, Clinical pharmacokinetics of Troglitazone. Clinical Pharmacokinetics, 37, 91-104.
17. Loi, C. M., Stern, R., Abel, R. et al., 1999b, Effect of troglitazone on pharmacokinetics and pharmacodynamics of atorvastatin. Clinical Pharmacology and Therapeutics, 65, PIII39.
18. Loi, C. M., Stern, R., Vassos, A. B. et al., 1998b, Effect of troglitazone on terfenadine pharmacokinetics. Clinical Pharmacology and Therapeutics, 63, 228.
19. Loi, C. M., Koup, J. R., Vassos, A. B. and Sedman, A. J., 1999c, Effect of TRZ on fexofenadine pharmacokonetics. Clinical Pharmacology and Therapeutics, 65, PIII40.
20. Loi, C. M., Stern, R., Koup, J. R. et al., 1999d, Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. Journal of Clinical Pharmacology, 39, 410-414.
21. Morris, D. L. and Davila, J. C., 1996, Analysis of rat cytochrome P450 isoenzyme expression using semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Biochemical Pharmacology, 52, 781-792.
22. Muntane-Relat, J., Ourlin, J. C., Domergue, J. and Maurel, P., 1995, Differential effects of cytokines on the inducible expression of CYP1A1, CYP 1A2 and CYP3A4 in human hepatocytes in primary culture. Hepatology, 22, 1143-1153.
23. Omiesinski, C. J., Hassett, C. and Costa, P., 1990, Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6 and CYP3A1. Molecular Pharmacology, 38, 462-470.
24. Parkinson, A., 1996, Biotransformation of xenobiotics. In C. D. Klaassen (ed.), Casarett and Doull's Toxicology. The Basic Science of Poisons, 5th edn (New York: McGraw-Hill), pp. 113-186.
25. Parkinson, A. and Gemzik, B., 1991, Production and purification of antibodies against rat liver P450 enzymes. Methods in Enzymology, 206, 233-245.
26. Pearce, R. E., McIntyre, C. J., Madan, A., Sanzgiri, U., Draper, A. J., Bullock, P. L., Cook, D. C., Burton, L. A., Latham, J., Nevins, C. and Parkinson, A., 1996, Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Archives of Biochemistry and Biophysics, 331, 145-169.
27. Rezulin ® Product Labelling (package insert), 1998, Warner-Lambert Co. (Morris Plains, NJ, USA).
28. Sidhu, J. S., Farin, F. M. and Omiecinski, C. J., 1993, Influence of extracellular matrix overlay on phenobarbital-mediated induction of CYP2B1, 2B2, and 3A1 genes in primary adult rat hepatocyte culture. Archives of Biochemistry and Biophysics, 30, 103-113.
29. Strom S. C., Pisarov, L. A., Dorko, K., Thompson, M. T., Schuetz, J. D. and Schuetz, E. G., 1996, Use of human hepatocytes to study P450 gene induction. Methods in Enzymology, 272, 388-401.
30. Vidal-Puig, A., Jiminez-Linan, M., Lowell, B. B. et al., 1996, Regulation of PPARγ gene expression by nutrition and obesity in rodents. Journal of Clinical Investigation, 97, 2553-2561.
31. Wortelboer, H. M., De Kruif, C. A,. Van Iersel, A. A. J., Falke, H. E., Noordhoek, J. and Blaauboer, B. J., 1990, The isoenzyme pattern of cytochrome P450 in rat hepatocytes in primary culture, comparing different enzyme activities in microsomal incubations and in intact monolayers. Biochemical Pharmacology, 40, 2525-2534.
32. Young, M. A., Lettis, S. and Eastmond, R., 1998, Concomitant administration of cholestyramine influences the absorption of troglitazone. British Journal of Clinical Pharmacology, 45, 37-40.